Beta Bionics (NASDAQ:BBNX) Research Coverage Started at Jefferies Financial Group

Jefferies Financial Group initiated coverage on shares of Beta Bionics (NASDAQ:BBNX) in a research report sent to investors on Monday morning, Marketbeat.com reports. The brokerage issued a buy rating and a $30.00 target price on the stock.

BBNX has been the subject of several other research reports. UBS Group restated a “buy” rating and issued a $25.00 target price on shares of Beta Bionics in a research report on Tuesday, September 15th. Bank of America lifted their target price on Beta Bionics from $18.00 to $20.00 and gave the stock a “neutral” rating in a report on Tuesday, September 15th. Robert W. Baird upped their price target on Beta Bionics from $14.00 to $16.00 and gave the company a “neutral” rating in a report on Tuesday, September 15th. Weiss Ratings raised shares of Beta Bionics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, August 18th. Finally, Truist Financial increased their target price on Beta Bionics from $23.00 to $28.00 and gave the company a “buy” rating in a report on Thursday, September 24th. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Beta Bionics currently has an average rating of “Moderate Buy” and a consensus target price of $24.00.

Beta Bionics Stock Performance

Shares of BBNX stock opened at $16.87 on Monday. Beta Bionics has a twelve month low of $8.80 and a twelve month high of $32.71. The firm has a fifty day simple moving average of $18.97 and a 200-day simple moving average of $15.14.

Beta Bionics (NASDAQ:BBNX) last released its quarterly earnings results on Wednesday, July 29th. The company reported ($0.53) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.62) by $0.09. Beta Bionics had a negative net margin of 61.31% and a negative return on equity of 26.30%. The business had revenue of $32.01 million during the quarter. As a group, equities analysts predict that Beta Bionics will post -2.02 earnings per share for the current fiscal year.

Insider Activity at Beta Bionics

In related news, insider Mark Hopman sold 36,870 shares of the stock in a transaction that occurred on Wednesday, September 9th. The stock was sold at an average price of $18.46, for a total transaction of $680,620.20. Following the completion of the sale, the insider owned 87,157 shares in the company, valued at $1,608,918.22. This represents a 29.73% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Steven Russell sold 4,221 shares of the firm’s stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $19.11, for a total value of $80,663.31. Following the completion of the sale, the insider directly owned 169,628 shares in the company, valued at $3,241,591.08. This trade represents a 2.43% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last 90 days, insiders have sold 97,697 shares of company stock valued at $1,907,034. 5.30% of the stock is owned by company insiders.

Institutional Trading of Beta Bionics

Several institutional investors have recently modified their holdings of BBNX. Caitong International Asset Management Co. Ltd boosted its stake in Beta Bionics by 1,075.7% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,987 shares of the company’s stock worth $61,000 after buying an additional 1,818 shares in the last quarter. Legal & General Group Plc acquired a new position in shares of Beta Bionics in the 2nd quarter valued at $62,000. The Manufacturers Life Insurance Company acquired a new position in shares of Beta Bionics in the 2nd quarter valued at $172,000. Ieq Capital LLC acquired a new position in shares of Beta Bionics in the 2nd quarter valued at $229,000. Finally, Quantbot Technologies LP acquired a new position in shares of Beta Bionics in the 2nd quarter valued at $264,000.

Key Beta Bionics News

Here are the key news stories impacting Beta Bionics this week:

• Positive Sentiment: Jefferies initiated coverage with a Buy rating and a $30 price target, implying substantial upside from the recent share price and providing a bullish Wall Street view. Beta Bionics upgraded to Strong Buy at Jefferies
• Neutral Sentiment: Multiple law firms reiterated that investors who purchased BBNX securities between July 30, 2025, and February 24, 2026, may seek appointment as lead plaintiff in a pending federal securities class action. The deadline is November 3, 2026. These announcements primarily seek investor participation and do not represent new company operating results. Kirby McInerney class action notice
• Negative Sentiment: The litigation alleges that Beta Bionics and certain executives misled investors by understating FDA concerns involving the iLet system. Claims cited in the notices include a June 2025 FDA Form 483, more than 18,000 allegedly unreported iLet complaints, and reports involving potentially life-threatening hypoglycemia. The disclosures allegedly preceded a stock decline of more than 37%, increasing uncertainty around regulatory compliance, product demand and possible litigation costs. Levi and Korsinsky Beta Bionics investor notice

About Beta Bionics

Beta Bionics, Inc is a medical technology company focused on developing and commercializing automated insulin delivery systems for people with insulin-requiring diabetes. Its lead product is the iLet Bionic Pancreas, an insulin pump system designed to automate much of the insulin-dosing process and reduce the daily burden associated with diabetes management.

The iLet Bionic Pancreas uses continuous glucose monitoring data and the company’s dosing algorithms to deliver insulin. Unlike conventional insulin pumps that generally require users to calculate meal doses, the system is designed to simplify mealtime dosing by using a person’s body weight and meal announcements as key inputs.